Worldwide sequence conservation of transmission-blocking vaccine candidate Pvs230 in Plasmodium vivax


Autoria(s): DOI, Masanori; TANABE, Kazuyuki; TACHIBANA, Shin-Lchiro; HAMAI, Meiko; TACHIBANA, Mayumi; MITA, Toshihiro; YAGI, Masanori; ZEYREK, Fadile Yildiz; FERREIRA, Marcelo U.; OHMAE, Hiroshi; KANEKO, Akira; RANDRIANARIVELOJOSIA, Milijaona; SATTABONGKOT, Jetsumon; CAO, Ya-Ming; HORII, Toshihiro; TORII, Motomi; TSUBOI, Takafumi
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

20/10/2012

20/10/2012

2011

Resumo

Pfs230, surface protein of gametocyte/gamete of the human malaria parasite, Plasmodium falciparum, is a prime candidate of malaria transmission-blocking vaccine. Plasmodium vivax has an ortholog of Pfs230 (Pvs230), however, there has been no study in any aspects on Pvs230 to date. To investigate whether Pvs230 can be a vivax malaria transmission-blocking vaccine, we performed evolutionary and population genetic analysis of the Pvs230 gene (pvs230: PVX_003905). Our analysis of Pvs230 and its orthologs in eight Plasmodium species revealed two distinctive parts: an interspecies variable part (IVP) containing species-specific oligopeptide repeats at the N-terminus and a 7.5 kb interspecies conserved part (ICP) containing 14 cysteine-rich domains. Pvs230 was closely related to its orthologs, Pks230 and Pcys230, in monkey malaria parasites. Analysis of 113 pvs230 sequences obtained from worldwide, showed that nucleotide diversity is remarkably low in the non-repeat 8-kb region of pvs230 (theta pi = 0.00118) with 77 polymorphic nucleotide sites, 40 of which results in amino acid replacements. A signature of purifying selection but not of balancing selection was seen on pvs230. Functional and/or structural constraints may limit the level of polymorphism in pvs230. The observed limited polymorphism in pvs230 should ground for utilization of Pvs230 as an effective transmission-blocking vaccine. (C) 2011 Elsevier Ltd. All rights reserved.

Ministry of Education, Culture, Sports, Science and Technology

Ministry of Education, Culture, Sports, Science and Technology[18073013]

Ministry of Education, Culture, Sports, Science and Technology[18GS03140013]

Ministry of Education, Culture, Sports, Science and Technology

Ministry of Education, Culture, Sports, Science and Technology[20390120]

Ministry of Education, Culture, Sports, Science and Technology

Ministry of Education, Culture, Sports, Science and Technology

Ministry of Education, Culture, Sports, Science and Technology[19406009]

Ministry of Education, Culture, Sports, Science and Technology

Ministry of Education, Culture, Sports, Science and Technology[21022034]

Ministry of Education, Culture, Sports, Science and Technology[22406012]

Ministry of Education, Culture, Sports, Science and Technology

Ministry of Health, Labour, and Welfare, Japan

Ministry of Health, Labour, and Welfare, Japan[H20-Shinkou-ippan-013]

Ministry of Health, Labour, and Welfare, Japan[H21-Chikyukibo-ippan-005]

Ministry of Health, Labour, and Welfare, Japan

Japan Society for the Promotion of Science (JSPS)

Japan Society for the Promotion of Science

National Institutes of Health of USA (NIH)[RO1 AI 075416-01]

U.S. National Institutes of Health (NIH)

Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)[470570/2006-7]

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Fundacao de Amparo Pesquisa do Estado de Sao Paulo (FAPESP)[05/51988-0]

Fundacao de Amparo Pesquisa do Estado de Sao Paulo (FAPESP)[07/51199-0]

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

National Natural Science Foundation of China

National Natural Science Foundation of China[30972774]

Identificador

VACCINE, v.29, n.26, p.4308-4315, 2011

0264-410X

http://producao.usp.br/handle/BDPI/28524

10.1016/j.vaccine.2011.04.028

http://dx.doi.org/10.1016/j.vaccine.2011.04.028

Idioma(s)

eng

Publicador

ELSEVIER SCI LTD

Relação

Vaccine

Direitos

restrictedAccess

Copyright ELSEVIER SCI LTD

Palavras-Chave #Malaria #Plasmodium vivax #Pvs230 #Gametocyte surface antigen #Purifying selection #Transmission-blocking vaccine #GAMETE-SURFACE PROTEIN #SIMIAN MALARIA PARASITES #TARGET ANTIGEN #POPULATION-STRUCTURE #ANTIBODY-RESPONSES #GENETIC DIVERSITY #DNA POLYMORPHISM #RURAL AMAZONIA #FALCIPARUM #PFS230 #Immunology #Medicine, Research & Experimental
Tipo

article

original article

publishedVersion